FDA updates needlestick rules:
This article was originally published in Clinica
The US FDA has updated its December 2002 guidance document on what should be included in a pre-market notification for anti-needlestick products. Most medical devices that include sharps injury prevention features are intravascular administration sets, piston syringes or hypodermic single-lumen needles. The guidance pertains only to the sharps injury prevention feature and does not cover the FDA's recommendations for the device itself, the agency said.
You may also be interested in...
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.